AI Terminal
DIACEUTICS PLC
Report Publication Announcement • Nov 30, 2023
7596_rns_2023-11-30_bbc1a11d-2f1e-4c47-ae78-ebe355f234d5.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 9754U
Diaceutics PLC
30 November 2023
Diaceutics to attend Stifel and LSE 'Best of British' Conference in NYC
Belfast and London, 30 November 2023 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical and biotech industry, announces that management will attend the Stifel 5th Annual 'Best of British' Discovery Conference at the London Stock Exchange's NYC offices on 13 December 2023.
Enquiries:
| Diaceutics PLC | |
| Peter Keeling, Chief Executive Officer | Tel: +44 (0)28 9040 6500 |
| Ryan Keeling, Chief Executive Officer Designate | [email protected] |
| Nick Roberts, Chief Financial Officer | |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Nick Harland | |
| Kate Hanshaw | |
| Alma Strategic Communications | Tel: +44(0)20 3405 0205 |
| Caroline Forde | [email protected] |
| Matthew Young | |
| Kinvara Verdon |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAEAEFPAELDFAA